Skip to Main Content

Paper Details

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Neuro Oncol
14
2023
BH3, BRAF, BRAF V600E, BRAF V600E mutation, BT40, BVD-523, DKFZ, DKFZ-BT66, ERK, ERK1/2, KIAA1549, MAPK, MEK, Patient, Patient-derived pLGG models, Pediatric low-grade gliomas, Ulixertinib, brain tumor, central nervous system tumors, low-grade glioma, mice, mitogen-activated protein kinase, mouse, pLGG, patients, pediatric, tumor, tumors, ulixertinib, zebrafish, zebrafish embryos
Author NameAffiliation
Andrey KorshunovHeidelberg University Hospital
Andrey KorshunovClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Andrey KorshunovHeidelberg University Hospital
Andrey KorshunovClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Felix SahmHeidelberg University Hospital
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Felix SahmHeidelberg University Hospital
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Cornelis M van TilburgHopp Children's Cancer Center Heidelberg (KiTZ)
Cornelis M van TilburgKiTZ Clinical Trial Unit, Heidelberg University Hospital
Cornelis M van TilburgClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ)
David T W JonesGerman Cancer Research Center (DKFZ)
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ)
David T W JonesGerman Cancer Research Center (DKFZ)
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterGerman Cancer Research Center (DKFZ)
Stefan M PfisterKiTZ Clinical Trial Unit, Heidelberg University Hospital
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ)
Stefan M PfisterKiTZ Clinical Trial Unit, Heidelberg University Hospital
Stefan M PfisterGerman Cancer Research Center (DKFZ)
Kristian W PajtlerHopp Children's Cancer Center Heidelberg (KiTZ)
Kristian W PajtlerKiTZ Clinical Trial Unit, Heidelberg University Hospital
Kristian W PajtlerGerman Cancer Research Center (DKFZ)
Kristian W PajtlerHopp Children's Cancer Center Heidelberg (KiTZ)
Kristian W PajtlerGerman Cancer Research Center (DKFZ)
Kristian W PajtlerKiTZ Clinical Trial Unit, Heidelberg University Hospital
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittKiTZ Clinical Trial Unit, Heidelberg University Hospital
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
Olaf WittKiTZ Clinical Trial Unit, Heidelberg University Hospital
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ)
Till MildeClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
Till MildeKiTZ Clinical Trial Unit, Heidelberg University Hospital
  • 1 - 36

Datasets